157
Participants
Start Date
August 31, 2005
Primary Completion Date
April 30, 2009
Study Completion Date
July 31, 2009
capecitabine [Xeloda]
825mg/m2 po bid on days 1-14 of each 3 week cycle
Taxotere
75mg/m2 iv on day 1 of each 3 week cycle
Herceptin (HER2-neu positive patients only)
4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
capecitabine [Xeloda]
825mg/m2 po bid on days 1-14 of each 3 week cycle
Taxotere
75mg/m2 iv on day 1 of each 3 week cycle
New York
Pittsburgh
Pottsville
Baltimore
Abingdon
Sumter
Charleston
Georgetown
Savannah
Melbourne
Miami
Tamarac
Memphis
Memphis
Canton
Indianapolis
Indianapolis
Iowa City
Edina
St Louis
Jefferson City
Rolla
Alexandria
Dallas
Albuquerque
Albuquerque
Santa Fe
Los Angeles
Montebello
San Diego
Palm Springs
Farmington
Scarborough
Neptune City
Albuquerque
Charlotte
Dallas
Burlington
Hoffmann-La Roche
INDUSTRY